Literature DB >> 29428182

Online Interactive Case-Based Instruction in Prostate Magnetic Resonance Imaging Interpretation Using Prostate Imaging and Reporting Data System Version 2: Effect for Novice Readers.

Andrew B Rosenkrantz1, Jovan Begovic2, Antonio Pires2, Eugene Won2, Samir S Taneja3, James S Babb2.   

Abstract

PURPOSE: To assess the effect on reader performance of an interactive case-based online tutorial for prostate magnetic resonance imaging (MRI) interpretation using Prostate Imaging and Reporting Data System (PI-RADS).
METHODS: An educational website was developed incorporating scrollable multiparametric prostate MRI examinations with annotated solutions based on PI-RADS version 2. Three second-year radiology residents evaluated a separate set of 60 prostate MRI examinations both before and after review of the online case material, identifying and scoring dominant lesions. These 60 examinations included 30 benign cases and 30 cases with a dominant lesion demonstrating Gleason score ≥3 + 4 tumor on fusion-targeted biopsy. The readers' pooled performance was compared between the 2 sessions using logistic regression and Wilcoxon signed rank tests.
RESULTS: All readers completed the online material within four-hours. Review of the online material significantly improved sensitivity (from 57.8%-73.3%, P = 0.003) and negative predictive value (from 69.2%-78.2%, P = 0.049), but not specificity (from 70.0%-67.8%, P = 0.692) or positive predictive value (from 59.6%-64.7%, P = 0.389). Reader confidence (1-10 scale; 10 = maximal confidence) also improved significantly (from 5.6 ± 2.7 to 6.3 ± 2.6, P = 0.026). However, accuracy of assigned PI-RADS scores did not improve significantly (from 45.5%-53.3%, P = 0.149).
CONCLUSION: An online interactive case-based website in prostate MRI interpretation improved novice readers' sensitivity and negative predictive value for tumor detection, as well as readers' confidence. This online material may serve as a resource complementing existing traditional methods of instruction by providing a more flexible educational experience among a larger volume of learners. However, further more targeted educational initiatives regarding the proper application of PI-RADS remain warranted.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29428182     DOI: 10.1067/j.cpradiol.2018.01.003

Source DB:  PubMed          Journal:  Curr Probl Diagn Radiol        ISSN: 0363-0188


  4 in total

Review 1.  Multiparametric MRI for prostate cancer diagnosis: current status and future directions.

Authors:  Armando Stabile; Francesco Giganti; Andrew B Rosenkrantz; Samir S Taneja; Geert Villeirs; Inderbir S Gill; Clare Allen; Mark Emberton; Caroline M Moore; Veeru Kasivisvanathan
Journal:  Nat Rev Urol       Date:  2019-07-17       Impact factor: 14.432

2.  Education of prostate MR imaging: commentary.

Authors:  Bryce A Merritt; Spencer C Behr
Journal:  Abdom Radiol (NY)       Date:  2020-12

3.  ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists' training.

Authors:  Maarten de Rooij; Bas Israël; Marcia Tummers; Hashim U Ahmed; Tristan Barrett; Francesco Giganti; Bernd Hamm; Vibeke Løgager; Anwar Padhani; Valeria Panebianco; Philippe Puech; Jonathan Richenberg; Olivier Rouvière; Georg Salomon; Ivo Schoots; Jeroen Veltman; Geert Villeirs; Jochen Walz; Jelle O Barentsz
Journal:  Eur Radiol       Date:  2020-05-19       Impact factor: 5.315

4.  Factors Influencing Variability in the Performance of Multiparametric Magnetic Resonance Imaging in Detecting Clinically Significant Prostate Cancer: A Systematic Literature Review.

Authors:  Armando Stabile; Francesco Giganti; Veeru Kasivisvanathan; Gianluca Giannarini; Caroline M Moore; Anwar R Padhani; Valeria Panebianco; Andrew B Rosenkrantz; Georg Salomon; Baris Turkbey; Geert Villeirs; Jelle O Barentsz
Journal:  Eur Urol Oncol       Date:  2020-03-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.